Dipan Mehta of Elixir Equities notes a mixed earnings season with disappointments in major sectors like banking and software. However, urban consumption shows promising signs in QSR, retail, hospitality, healthcare, and travel. Mehta advises selectivity, favoring pharma companies with differentiated models, particularly CDMOs, while remaining cautious due to potential tariff impacts and base effects.
Pankaj Tibrewal sees stronger top-line growth driving India’s next earnings cycle
Indian companies are poised to navigate input cost pressures and sustain growth, with the upcoming earnings season expected to be the next market trigger. Experts
June 30, 2026